HLA-DQ2 & DQ8 Allele Test for Celiac Disease at Chughtai Lab

HLA-DQ2 & DQ8 Allele Detection for Celiac Disease at Chughtai Lab

HLA-DQ2 & DQ8 Allele Detection is a highly specialized molecular diagnostic test used to identify genetic susceptibility to celiac disease. Celiac disease is a chronic, systemic, autoimmune-mediated enteropathy triggered by the ingestion of dietary gluten (a protein found in wheat, rye, and barley) in genetically predisposed individuals. This genetic predisposition is primarily linked to the human leukocyte antigen (HLA) class II genes, specifically those encoding the HLA-DQ2 and HLA-DQ8 heterodimers. Chughtai Lab, a premier diagnostic network in Pakistan, performs this advanced molecular assay using state-of-the-art polymerase chain reaction (PCR) technology to provide clinicians and patients with definitive genetic insights.

The human leukocyte antigen system is a complex gene family located on chromosome 6 that plays a pivotal role in the immune system's ability to distinguish self from non-self. In individuals who carry the HLA-DQ2 or HLA-DQ8 alleles, antigen-presenting cells display a high affinity for deamidated gliadin peptides (components of gluten). When gluten is ingested, the enzyme tissue transglutaminase (tTG) deamidates gliadin, allowing it to bind tightly to the HLA-DQ2 or HLA-DQ8 receptors on antigen-presenting cells. This binding triggers an abnormal CD4+ T-cell-mediated immune response, leading to chronic inflammation of the small intestinal mucosa, villous atrophy, crypt hyperplasia, and subsequent malabsorption of essential nutrients.

The clinical importance of HLA-DQ2 & DQ8 testing lies in its extraordinary negative predictive value, which exceeds 99%. Because the presence of these alleles is an absolute prerequisite for the development of celiac disease, a negative result effectively rules out the condition for a patient's entire lifetime. Conversely, the test has a low positive predictive value, as approximately 30% to 40% of the general healthy population carries these alleles without ever developing the disease. Therefore, this test is not used to diagnose active celiac disease on its own, but rather to exclude the diagnosis, stratify genetic risk, and guide further clinical investigations in complex diagnostic scenarios.

Clinical Procedure: What to Expect

Patient Preparation

Unlike serological tests for celiac disease (such as tissue transglutaminase IgA or deamidated gliadin peptide IgG), which require the patient to maintain a gluten-containing diet to ensure accuracy, genetic testing is unaffected by dietary habits. Because DNA sequences do not change in response to diet, patients do not need to alter their eating patterns prior to the test. The specific preparation guidelines include:

• No Dietary Restrictions: The patient can continue a gluten-free or gluten-containing diet without affecting the test results.
• No Fasting Required: Fasting is not necessary for this molecular test; blood samples can be collected at any time of the day.
• Medication History: Patients should inform the healthcare provider of any recent blood transfusions or bone marrow transplants, as these can temporarily affect genetic testing results.
• Hydration: Maintaining adequate hydration is recommended to facilitate easier venous access during sample collection.

During the Procedure

The HLA-DQ2 & DQ8 Allele Detection test is performed on a peripheral blood sample. The procedure is straightforward, safe, and completed within a few minutes:

• Patient Identification and Verification: The phlebotomist verifies the patient's identity and explains the procedure.
• Venipuncture Site Selection: A suitable vein, typically in the antecubital fossa (inner elbow), is selected and cleansed with an antiseptic solution.
• Sample Collection: A small volume of whole blood (approximately 3 to 5 mL) is drawn into an ethylenediaminetetraacetic acid (EDTA) tube (purple-top tube), which prevents blood clotting and preserves the integrity of cellular DNA.
• Post-Collection Care: Pressure is applied to the puncture site with a sterile cotton ball, and a bandage is applied to prevent bruising.
• DNA Extraction and Analysis: The sample is transported to Chughtai Lab's specialized molecular biology division, where genomic DNA is extracted from white blood cells and subjected to PCR amplification and sequence-specific primer (PCR-SSP) analysis or real-time PCR to detect the specific alleles.

When is an HLA-DQ2 & DQ8 Allele Detection Test Performed?

Screening High-Risk Family Members

Celiac disease has a strong genetic component, with first-degree relatives of affected individuals having a 10% to 15% risk of developing the condition. Clinicians frequently request HLA testing for asymptomatic family members. If a relative tests negative for both HLA-DQ2 and HLA-DQ8, they can be reassured that they have virtually zero risk of developing celiac disease, eliminating the need for periodic serological screening throughout their lives.

Resolving Ambiguous or Discrepant Diagnostic Results

In clinical practice, diagnostic discrepancies often arise. For example, a patient may present with symptoms suggestive of celiac disease and show positive serological markers, but a small bowel biopsy may reveal normal or equivocal mucosal architecture (Marsh class 0 or 1). Alternatively, a patient may have histological changes suggestive of celiac disease but negative serology. HLA testing helps resolve these diagnostic dilemmas by confirming or excluding genetic susceptibility.

Evaluating Patients Already on a Gluten-Free Diet

Many individuals self-initiate a gluten-free diet before undergoing formal diagnostic evaluation. Once gluten is removed from the diet, serological markers normalize and the intestinal mucosa heals, making standard diagnostic tests (biopsy and serology) unreliable. To perform these tests accurately, patients must undergo a prolonged, often uncomfortable gluten challenge. HLA testing is an invaluable first step in this population; if the patient is negative for HLA-DQ2/DQ8, celiac disease is ruled out, and the challenging gluten trial can be avoided entirely.

Investigating Seronegative Celiac Disease Suspects

Approximately 2% to 5% of patients with biopsy-confirmed celiac disease do not produce detectable levels of celiac-specific antibodies (seronegative celiac disease). This is particularly common in individuals with selective immunoglobulin A (IgA) deficiency, which occurs at a much higher frequency in celiac patients than in the general population. In such cases, identifying the presence of HLA-DQ2 or HLA-DQ8 alleles provides essential supportive evidence to justify further invasive diagnostic steps or a trial of a gluten-free diet.

Assessment of Patients with Associated Autoimmune and Genetic Conditions

Certain genetic and autoimmune disorders are highly associated with an increased prevalence of celiac disease. These include Type 1 Diabetes Mellitus, autoimmune thyroiditis (Hashimoto's thyroiditis), Down syndrome, Turner syndrome, and Williams syndrome. Pediatricians and endocrinologists often order HLA-DQ2 & DQ8 testing in these patient populations to screen out those who have no genetic risk, thereby focusing clinical surveillance only on those who carry the susceptibility genes.

What Does an HLA-DQ2 & DQ8 Allele Detection Test Detect?

The molecular assay specifically targets and identifies the presence or absence of the genetic sequences that code for the alpha and beta chains of the HLA-DQ2 and HLA-DQ8 heterodimers. The test detects and reports on the following specific genetic parameters:

• HLA-DQ2.5 Heterodimer: This is the highest-risk genotype for celiac disease, encoded by the DQA1*05 and DQB1*02 alleles in cis or trans configuration. It is present in approximately 90% of celiac patients.
• HLA-DQ2.2 Heterodimer: Encoded by the DQA1*02 and DQB1*02 alleles, this variant carries a lower risk than DQ2.5 but is still clinically significant, particularly when combined with other risk alleles.
• HLA-DQ8 Heterodimer: Encoded by the DQA1*03 and DQB1*03:02 alleles, this genotype is found in approximately 5% to 10% of celiac patients, particularly those of specific ethnic backgrounds or those who present with atypical symptoms.
• Allele Dosage (Homozygosity vs. Heterozygosity): The test determines whether a patient carries one copy (heterozygous) or two copies (homozygous) of the risk alleles. Homozygosity for DQ2.5 or DQB1*02 is associated with a significantly higher risk of developing celiac disease and a higher likelihood of classical, severe clinical presentations, including refractory celiac disease.
• Absence of Risk Alleles: The complete absence of both HLA-DQ2 and HLA-DQ8 alleles, confirming that celiac disease is highly improbable.
• Genetic Predisposition to Dermatitis Herpetiformis: This cutaneous manifestation of gluten sensitivity shares the exact same genetic association with HLA-DQ2 and DQ8.
• MHC Class II Genetic Variations: General variations within the major histocompatibility complex that assist in clinical risk stratification.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab utilizes highly automated, state-of-the-art molecular diagnostic platforms to ensure the highest level of precision and rapid processing of genetic assays. Because molecular testing involves complex steps, including DNA extraction, quality control, PCR amplification, and expert interpretation by molecular pathologists, the turnaround time for the HLA-DQ2 & DQ8 Allele Detection test is typically within 5 to 7 working days.

Once the analysis is complete, Chughtai Lab offers multiple convenient pathways for patients and referring physicians to access the diagnostic reports. Patients receive an automated SMS notification containing a direct link to download their report. Reports can also be accessed securely online through the official Chughtai Lab website portal or via the Chughtai Lab Mobile App. Additionally, patients can obtain their reports through Chughtai Lab's dedicated WhatsApp service or collect a printed copy from any of the numerous Chughtai Lab collection centers located across Pakistan.

HLA-DQ2 & DQ8 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HLA-DQ2.5 Allele (DQA1*05 / DQB1*02)	Not Detected	Detected (Associated with the highest genetic risk for celiac disease)
HLA-DQ8 Allele (DQA1*03 / DQB1*03:02)	Not Detected	Detected (Associated with moderate-to-high genetic risk for celiac disease)
HLA-DQ2.2 Allele (DQA1*02 / DQB1*02)	Not Detected	Detected (Associated with low-to-moderate risk; clinically relevant)
Overall Genetic Susceptibility	Negative (No HLA-DQ2 or DQ8 alleles detected)	Positive (One or more risk alleles detected; genetic susceptibility confirmed)
Zygosity Status (Allele Dosage)	Non-carrier / Heterozygous (Single copy)	Homozygous (Double copy; associated with increased risk and severity)
DNA Quality and Concentration	Adequate for PCR amplification	Inadequate DNA yield (Requires sample recollection)
Clinical Interpretation	Celiac disease ruled out (>99% negative predictive value)	Genetic predisposition present; requires clinical correlation (serology/biopsy)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HLA-DQ2 & DQ8 Allele Detection?

• Advanced Molecular Diagnostics: Chughtai Lab utilizes cutting-edge PCR and genetic analysis technology to deliver highly accurate molecular results.
• Experienced Pathologists: Reports are interpreted and signed off by qualified molecular pathologists and clinical geneticists.
• Extensive Network: With hundreds of collection centers across Pakistan, accessing specialized genetic testing is highly convenient.
• Home Sample Collection: Chughtai Lab offers professional home sample collection services, allowing patients to have their blood drawn in the comfort of their homes.
• Strict Quality Control: The laboratory adheres to international quality assurance protocols and participates in external quality assessment programs.
• Digital Report Access: Quick and secure access to reports via the Chughtai Lab Mobile App, website, and WhatsApp.
• Patient-Focused Care: A dedicated customer support team is available to assist patients with booking, preparation guidelines, and report queries.
• Comprehensive Diagnostic Services: Chughtai Lab offers a complete suite of celiac disease investigations, including serology (tTG IgA/IgG) and histopathology, allowing for seamless follow-up testing.